Literature DB >> 30466691

Skin Cancer and Immunosuppression.

Lindsey Collins1, Andrew Quinn2, Thomas Stasko2.   

Abstract

Immunosuppressed patients are at significantly increased risk of developing cutaneous malignancies. These malignancies are often more aggressive compared with the general population and require multidisciplinary care. This article highlights the incidence and risk factors of cutaneous malignancies in this cohort. The treatment and prevention strategies are discussed. There continues to be a need for evidence-driven guidelines regarding the management of skin cancers in these patients.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemoprevention; Human papillomavirus; Immunosuppression; Melanoma; Mohs micrographic surgery; Nonmelanoma skin cancer; Organ transplant recipients; Squamous cell carcinoma

Mesh：

Year:  2018        PMID： 30466691     DOI： 10.1016/j.det.2018.07.009

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN： 0733-8635            Impact factor:   3.478


  8 in total

1.  Medical Immunosuppression and Outcomes in Cutaneous Melanoma: A Population-Based Cohort Study.

Authors:  Jessica Bogach; Frances C Wright; Janice Austin; Stephanie Y Cheng; Christina Diong; Rinku Sutradhar; Nancy N Baxter; Nicole J Look Hong
Journal:  Ann Surg Oncol       Date:  2020-10-16       Impact factor: 5.344

2.  Common genetic polymorphisms contribute to the association between chronic lymphocytic leukaemia and non-melanoma skin cancer.

Authors:  Caroline Besson; Amy Moore; Wenting Wu; Claire M Vajdic; Silvia de Sanjose; Nicola J Camp; Karin E Smedby; Tait D Shanafelt; Lindsay M Morton; Jerry D Brewer; Lydia Zablotska; Eric A Engels; James R Cerhan; Susan L Slager; Jiali Han; Sonja I Berndt
Journal:  Int J Epidemiol       Date:  2021-08-30       Impact factor: 7.196

3.  Development of Two Types of Skin Cancer in a Patient with Systemic Sclerosis: a Case Report and Overview of the Literature.

Authors:  Firdevs Ulutaş; Erdem Çomut; Veli Çobankara
Journal:  Case Rep Oncol Med       Date:  2021-02-26

Review 4.  Skin cancer biology and barriers to treatment: Recent applications of polymeric micro/nanostructures.

Authors:  Nazeer Hussain Khan; Maria Mir; Lei Qian; Mahnoor Baloch; Muhammad Farhan Ali Khan; Asim-Ur- Rehman; Ebenezeri Erasto Ngowi; Dong-Dong Wu; Xin-Ying Ji
Journal:  J Adv Res       Date:  2021-06-16       Impact factor: 10.479

5.  Extraocular sebaceous carcinoma in a renal transplant patient: A case report.

Authors:  Refka Frioui; Faten Rabhi; Faten Gargouri; Kahena Jaber; Mohamed Raouf Dhaoui
Journal:  Clin Case Rep       Date:  2022-06-19

6.  Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.

Authors:  Ulrike Leiter; Carmen Loquai; Lydia Reinhardt; David Rafei-Shamsabadi; Ralf Gutzmer; Katharina Kaehler; Lucie Heinzerling; Jessica C Hassel; Valerie Glutsch; Judith Sirokay; Nora Schlecht; Albert Rübben; Thilo Gambichler; Kerstin Schatton; Claudia Pfoehler; Cindy Franklin; Patrick Terheyden; Sebastian Haferkamp; Peter Mohr; Lena Bischof; Elisabeth Livingstone; Lisa Zimmer; Michael Weichenthal; Dirk Schadendorf; Andreas Meiwes; Ulrike Keim; Claus Garbe; Jürgen Christian Becker; Selma Ugurel
Journal:  J Immunother Cancer       Date:  2020-10       Impact factor: 13.751

Review 7.  Drug-Drug Interactions in Vestibular Diseases, Clinical Problems, and Medico-Legal Implications.

Authors:  Giulio Di Mizio; Gianmarco Marcianò; Caterina Palleria; Lucia Muraca; Vincenzo Rania; Roberta Roberti; Giuseppe Spaziano; Amalia Piscopo; Valeria Ciconte; Nunzio Di Nunno; Massimiliano Esposito; Pasquale Viola; Davide Pisani; Giovambattista De Sarro; Milena Raffi; Alessandro Piras; Giuseppe Chiarella; Luca Gallelli
Journal:  Int J Environ Res Public Health       Date:  2021-12-08       Impact factor: 3.390

Review 8.  Integrin αE(CD103)β7 in Epithelial Cancer.

Authors:  Johanna C Hoffmann; Michael P Schön
Journal:  Cancers (Basel)       Date:  2021-12-09       Impact factor: 6.639
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.